Current stock page

Catalysts

TGTX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

TGTXTG Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$64.51−$0.05 (−0.08%)

Latest quote

  • Momentum
    93
  • Value
    65
  • Quality
    69
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 76/100

Momentum 93/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 45.89%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 93/100AIQ Edge 10/10 Sector Leader
Beat rate
25%
2 of 8 reported periods
Average surprise
+85.6%
Across covered historical reports
Latest result
-2.6%
Nov 9, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 9, 2026—$0.36$0.35-2.6%$245.47M$259.94M
Aug 3, 2026—$0.31$0.05-83.6%$229.77M$240.34M
May 6, 2026—$0.23$0.14-39.1%$200.33M$204.92M
Feb 26, 2026—$0.35$0.14-60.0%$191.79M$192.57M
Nov 3, 2025—$0.24$2.43+912.5%$193.8M$161.71M
Aug 4, 2025—$0.32$0.17-46.9%$146.27M$141.15M
May 5, 2025—$0.18$0.03-83.3%$134.2M$120.86M
Mar 3, 2025—$0.08$0.15+87.5%$108.8M$108.19M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
7
Buy
1
Sell
12-month analyst target
—
— versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
No analyst target path in this snapshot.
Low target
—
—
Average target
—
—
High target
—
—

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate$0.56

Current analyst expectation for the upcoming report.

Revenue estimate$290.22M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score93

Where event reaction would show up first.

AIQ score76/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
5
Neutral
0
Negative
0
seekingalpha.com · Nov 9, 2026

TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript

TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call November 9, 2026 8:30 AM ESTCompany ParticipantsJenna Bosco - Senior Vice President of Corporate...

gurufocus.com · Nov 9, 2026

TD Cowen Raises Forecast for TG Therapeutics (TGTX) on Briumvi's Strong Market Momentum

On November 09, 2026, TD Cowen highlighted the accelerating adoption of TG Therapeutics Inc's (NASDAQ: TGTX) flagship drug Briumvi, raising its financial outloo

gurufocus.com · Nov 9, 2026

TG Therapeutics (TGTX) Q3 2026 Earnings Beat Revenue Estimates, Raises Full-Year Guidance

On November 09, 2026, TG Therapeutics Inc (NASDAQ: TGTX) reported its third-quarter financial results, posting a GAAP EPS slightly below expectations but delive

seekingalpha.com · Oct 27, 2026

TG Therapeutics: The Business Is More Attractive Than The Valuation (NASDAQ:TGTX)

TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance and approaching blockbuster status. Learn why TGTX stock is a hold.

gurufocus.com · Oct 23, 2026

TG Therapeutics (TGTX) Reports Promising Phase 1 Data on Novel CAR T-Cell Therapy for Progressive MS

On October 23, 2026, TG Therapeutics Inc (NASDAQ: TGTX) announced preliminary results from its Phase 1 clinical trial evaluating azercabtagene zapreleucel, a pi

Open full news and sentiment

TGTX Catalysts FAQ

What are the next catalysts for TGTX stock?

TGTX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TGTX stock?

Upcoming events that could move TGTX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TGTX's next earnings report affect the stock?

TGTX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TGTX stock higher?

TGTX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TGTX stock?

TGTX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.